Arvinas Plunges 20.63% as Bearish Signals Dominate

Market Snapshot

Arvinas (ARVN.O) is in a technically weak state, with bearish signals dominating the recent five-day technical analysis. Analysts remain largely negative, and the price has fallen by -20.63% in the last 20 days, despite some positive inflows at the institutional level.

News Highlights

Recent news affecting Arvinas and the broader market includes:

• Pharma patent expiry: Novo Nordisk's patent for semaglutide is set to expire in India, opening the door for cheaper weight-loss drug alternatives. This could indirectly affect Arvinas if it competes in similar therapeutic areas.
• H-1B visa reform: A new US bill aims to waive the $100,000 H-1B visa fee for doctors and nurses, potentially easing staffing pressures in healthcare—possibly impacting the biotech sector's hiring and R&D momentum.
• Reflation concerns: Greenlight Capital’s David Einhorn has increased bets on re-inflation, signaling potential inflationary pressures. This could indirectly increase borrowing costs and pressure companies with high leverage or high debt.

Analyst Views & Fundamentals

Arvinas is receiving a mixed but overall negative analyst outlook. The simple average rating score is 4.00, while the performance-weighted rating is a much lower 0.58, indicating a significant divergence between analysts and actual returns.

Analysts from Citigroup, Evercore ISI Group, Piper Sandler, and Wedbush have all rated Arvinas as "Underperform" or "Buy" in the past 20 days, with historical win rates ranging from 0.0% to 33.3%. These ratings show little correlation with the stock's negative price performance.

Key fundamental factors (based on proprietary internal diagnostic scores) are:

• Total operating revenue (YoY growth): -0.30% – score: 1.43 (very weak growth)
• Days sales outstanding: 4.59% – score: 2.00 (better than average)
• Inventory turnover ratio: 107.53% – score: 2.00 (high turnover is positive)
• PB-ROE: 7.39% – score: 3.90 (modest profitability)
• Annualized return on total assets: -13.14% – score: 1.00 (poor performance)
• Cost of sales ratio: 56.85% – score: 2.00 (high cost burden)
• Asset-MV: -54.72% – score: 7.65 (strong asset value)

Money-Flow Trends

Big money and small investors are sending mixed signals for Arvinas. While large, extra-large, and block capital flows are all positive or neutral (inflow ratios between 49.28% and 51.80%), the small-investor trend is negative (49.28% inflow ratio but overall negative trend).

Overall, the fund flow score is 7.65 (good), suggesting that institutional investors are more optimistic about the stock than the retail crowd. This divergence could indicate a potential divergence in near-term price action between big and small players.

Key Technical Signals

Technically, Arvinas is in a weak state, with 3 bearish and only 0 bullish indicators in the last 5 days. The technical score is 4.0 out of 10, indicating caution is needed.

• MACD Death Cross (2026-03-12) – score: 1.00 (very bearish)
• Long Upper Shadow (2026-03-09) – score: 2.60 (weak bearish signal)
• Long Lower Shadow and Hanging Man (2026-03-06) – scores: 3.77 and 5.79, respectively (neutral to bearish)

These signals point to uncertainty and volatility, with no clear upward momentum. The market is in a technically weak and volatile phase, and traders should remain cautious until a clear breakout occurs.

Conclusion

Arvinas is facing a mixed outlook with technically bearish signals, weak analyst ratings, and a recent price decline of -20.63%. However, institutional fund flows remain positive and could support a short-term rebound.

Investors are advised to consider waiting for a clearer trend confirmation before entering long positions. A pull-back with strong volume could be an entry point, but for now, the stock remains a high-risk, high-volatility play.